← Back to Screener
Mesoblast Limited American Depositary Shares (MESO)
Price$16.09
Favorite Metrics
Price vs S&P 500 (26W)-28.05%
Price vs S&P 500 (4W)1.35%
Market Capitalization$2.80B
All Metrics
Book Value / Share (Quarterly)$0.45
P/TBV (Annual)9.47x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)18.97%
Cash Flow / Share (Quarterly)$-0.05
Price vs S&P 500 (YTD)-19.53%
Gross Margin (TTM)57.98%
Net Profit Margin (TTM)-144.33%
EPS (TTM)$-0.07
10-Day Avg Trading Volume5.76M
EPS Excl Extra (TTM)$-0.07
Revenue Growth (5Y)-11.76%
EPS (Annual)$-0.08
ROI (Annual)-14.08%
Gross Margin (Annual)70.17%
Net Profit Margin (5Y Avg)-1079.10%
Cash / Share (Quarterly)$0.10
Revenue Growth QoQ (YoY)1526.81%
ROA (Last FY)-13.02%
Revenue Growth TTM (YoY)1053.16%
EBITD / Share (TTM)$-0.06
ROE (5Y Avg)-17.42%
Operating Margin (TTM)-115.66%
Cash Flow / Share (Annual)$-0.04
P/B Ratio3.49x
P/B Ratio (Quarterly)4.48x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)30.78x
Net Interest Coverage (TTM)-4.56x
ROA (TTM)-12.04%
EPS Incl Extra (Annual)$-0.08
Current Ratio (Annual)1.99x
Quick Ratio (Quarterly)1.35x
3-Month Avg Trading Volume4.21M
52-Week Price Return38.27%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.11
P/S Ratio (Annual)116.71x
Asset Turnover (Annual)0.02x
52-Week High$3.31
Operating Margin (5Y Avg)-873.47%
EPS Excl Extra (Annual)$-0.08
CapEx CAGR (5Y)-20.16%
Tangible BV CAGR (5Y)9.39%
26-Week Price Return-24.07%
Quick Ratio (Annual)1.72x
13-Week Price Return-17.95%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)1.58x
Enterprise Value$2,012.75
Revenue / Share Growth (5Y)-25.24%
Asset Turnover (TTM)0.08x
Book Value / Share Growth (5Y)-13.18%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-592.00%
Cash / Share (Annual)$0.13
3-Month Return Std Dev60.19%
Gross Margin (5Y Avg)-181.16%
Net Income / Employee (TTM)$-1
ROE (Last FY)-17.10%
Net Interest Coverage (Annual)-5.06x
EPS Basic Excl Extra (Annual)$-0.08
Receivables Turnover (TTM)2.95x
Total Debt / Equity (Quarterly)0.24x
EPS Incl Extra (TTM)$-0.07
Receivables Turnover (Annual)2.25x
ROI (TTM)-13.15%
P/S Ratio (TTM)30.70x
Pretax Margin (5Y Avg)-1082.59%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$0.13
Price vs S&P 500 (52W)8.44%
Year-to-Date Return-17.65%
5-Day Price Return5.66%
EPS Normalized (Annual)$-0.08
ROA (5Y Avg)-13.09%
Net Profit Margin (Annual)-593.92%
Month-to-Date Return3.70%
Cash Flow / Share (TTM)$-0.16
EBITD / Share (Annual)$-0.07
Operating Margin (Annual)-480.93%
LT Debt / Equity (Annual)0.11x
ROI (5Y Avg)-14.30%
LT Debt / Equity (Quarterly)0.10x
EPS Basic Excl Extra (TTM)$-0.07
P/TBV (Quarterly)18.33x
P/B Ratio (Annual)2.54x
Pretax Margin (TTM)-143.47%
Book Value / Share (Annual)$0.47
Price vs S&P 500 (13W)-18.64%
Beta2.35x
P/FCF (Annual)18.90x
Revenue / Share (TTM)$0.05
ROE (TTM)-16.10%
52-Week Low$1.52
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MESOMesoblast Limited American Depositary Shares | 30.70x | 1053.16% | 57.98% | — | $16.09 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Mesoblast is a commercial-stage biotechnology company developing allogeneic cellular medicines for serious inflammatory and degenerative diseases. Key programs include Ryoncil for steroid-refractory acute graft-versus-host disease and acute respiratory distress syndrome, Revascor for chronic heart failure, and a candidate for chronic low back pain. The company leverages a proprietary adult stem cell technology platform designed for off-the-shelf therapeutic applications.